{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jia S"],"funding":["National Natural Science Foundation of China","Jiangsu Provincial Key Project of Science and Technology Plan","Science Fund for Distinguished Young Scholars of Jiangsu Province"],"pagination":["2448405"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11776483"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(1)"],"pubmed_abstract":["INO-4800 represents a DNA-based vaccine encoding the spike protein of SARS-CoV-2. This phase 2 trial evaluated the immunogenicity and safety of INO-4800 as a primary vaccination series in adults. We conducted a randomized, observer-blind, placebo-controlled phase 2 trial of intradermal injection of INO-4800 in both healthy adults and elderly individuals. Eligible participants from each age group were enrolled and randomly assigned in a 3:3:2 ratio to receive two doses of INO-4800 (1.0 mg or 2.0 mg) or placebo, followed by electroporation on day 0 and day 28. The primary immunogenicity endpoints focused on determining the geometric mean titers (GMTs) of spike-binding antibodies and live SARS-CoV-2 neutralizing antibody at day 30 after the second dose. The primary endpoint for safety was the"],"journal":["Human vaccines & immunotherapeutics"],"pubmed_title":["Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial."],"pmcid":["PMC11776483"],"funding_grant_id":["BE2021738","82341031","BK20220064"],"pubmed_authors":["Xia Y","Li J","Leng D","Wang B","Zhu F","Cheng X","Wang J","Xu J","Shao C","Pan H","Jia S","Huai X","Zhao G","Wang Z"],"additional_accession":[]},"is_claimable":false,"name":"Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial.","description":"INO-4800 represents a DNA-based vaccine encoding the spike protein of SARS-CoV-2. This phase 2 trial evaluated the immunogenicity and safety of INO-4800 as a primary vaccination series in adults. We conducted a randomized, observer-blind, placebo-controlled phase 2 trial of intradermal injection of INO-4800 in both healthy adults and elderly individuals. Eligible participants from each age group were enrolled and randomly assigned in a 3:3:2 ratio to receive two doses of INO-4800 (1.0 mg or 2.0 mg) or placebo, followed by electroporation on day 0 and day 28. The primary immunogenicity endpoints focused on determining the geometric mean titers (GMTs) of spike-binding antibodies and live SARS-CoV-2 neutralizing antibody at day 30 after the second dose. The primary endpoint for safety was the","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-01T08:56:37.366Z","creation":"2025-04-04T22:23:26.342Z"},"accession":"S-EPMC11776483","cross_references":{"pubmed":["39865693"],"doi":["10.1080/21645515.2024.2448405"]}}